WO2007105981A1 - Forme orale solide d'une préparation médicinale et procédé de production de celle-ci - Google Patents
Forme orale solide d'une préparation médicinale et procédé de production de celle-ci Download PDFInfo
- Publication number
- WO2007105981A1 WO2007105981A1 PCT/RU2006/000237 RU2006000237W WO2007105981A1 WO 2007105981 A1 WO2007105981 A1 WO 2007105981A1 RU 2006000237 W RU2006000237 W RU 2006000237W WO 2007105981 A1 WO2007105981 A1 WO 2007105981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid oral
- antibodies
- antibody
- pharmaceutically acceptable
- dilution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the invention relates to medicine and can be used for the technologically simple preparation of a solid oral antibody-based drug for the effective treatment of a pathological syndrome without significant side effects.
- medications serums, immunoglobulins
- antibodies used in therapeutic doses
- these drugs are prepared in liquid dosage form for injection and injected into the body parenterally, since only with this method of administration the bioavailability of these drugs is ensured.
- the invention is directed to the creation of a solid form of a drug based on antibodies suitable for oral administration. denia, and a technologically simple way to obtain a drug based on antibodies in an activated form prepared according to homeopathic technology in the form of tablets.
- the solid oral form of the antibody-based drug product includes an effective amount of a carrier irrigated with water-alcohol dilution of antibodies in an activated form prepared by combining multiple serial dilutions of antibodies and external exposure, and pharmaceutically acceptable additives.
- water-alcohol dilution contains, in an activated form, antibodies to an endogenous substance involved in the regulation or affecting the mechanisms of formation of a pathological syndrome, the activated form being prepared by repeated serial dilution and external exposure according to homeopathic technology.
- the drug contains a neutral substance - lactose
- a pharmaceutically acceptable additive contains a binder and a glidant.
- the additionally solid oral form contains a neutral filler - lactose in an amount of 30 ⁇ 80 mass. % of the mass of solid oral form - tablets, while in the capacity of a binder contains microcrystalline cellulose in an amount of 10.0 ⁇ 15.0 mass. % of the mass of solid oral form - tablets, and as a moving substance - magnesium stearate in an amount of 0.8 ⁇ 1.2 mass. % by weight of solid oral form - tablets.
- the activated form of antibodies is a mixture of various decimal and / or hundreds of water-alcohol homeopathic dilutions.
- the method of obtaining a solid oral form of a drug based on antibodies involves the preparation of a water-alcohol dilution of antibodies in an activated form, obtained by combining multiple serial dilutions and external exposure using homeopathic technology, irrigation with a water-alcohol dilution of a neutral carrier in a fluidized - fluidized bed with simultaneous drying at a temperature not exceeding 35 0 C, mixing in pharmaceutically acceptable sequence with pharmaceutically acceptable additives, and subsequent tabletting — tablet formation by direct dry compression.
- a neutral substance lactose, with a particle size of 150 to 250 microns, is used as a carrier.
- the introduction into the solid dosage form of antibodies in the activated form provides the possibility of oral administration of a drug based on antibodies while maintaining biological activity.
- the qualitative, quantitative, particle size and structural composition of the claimed ingredients provides the possibility of reliable formation of tablets directly dry pressing using a limited number of additives.
- Polyclonal antibodies, monoclonal antibodies, and natural antibodies to a substance involved in the regulation or affecting the mechanisms of formation of a pathological syndrome are used to prepare a pharmaceutical substance.
- Polyclonal antibodies that specifically bind to compounds of various classes — proteins, polynucleotides, oligosaccharides, glycolipids, etc., as well as interacting with low molecular weight substances (haptens) are obtained by active immunization of animals.
- an antigen which is either an individually isolated high molecular weight substance, or is a synthetic conjugate - in the case of using haptens.
- an antigen which is either an individually isolated high molecular weight substance, or is a synthetic conjugate - in the case of using haptens.
- an antigen which is either an individually isolated high molecular weight substance, or is a synthetic conjugate - in the case of using haptens.
- an antigen which is either an individually isolated high molecular weight substance, or is a synthetic conjugate - in the case of using haptens.
- an antigen which is either an individually isolated high molecular weight substance, or is a synthetic conjugate - in the case of using haptens.
- Monoclonal antibodies of various specificity interacting with both low molecular weight haptenes and epitopes of high molecular weight substances are obtained using hybridoma technology.
- the initial stage of the process includes immunization, based on the principles already developed in the preparation of research institutes of polyclonal antisera. Further stages of the work include obtaining hybrid cells producing clones of antibodies of the same specificity. Their isolation in an individual form is carried out by the same methods as in the case of polyclonal antisera.
- Natural antibodies to exogenous antigens and bioregulators of various nature are isolated from human blood serum by affinity chromatography.
- a carrier with a covalently bound antigen which is either a hapten or a macromolecular compound, is used as an immunosorbent.
- chromatography a population of antibodies with a narrow distribution of specificity and affinity is obtained.
- Isolated antibodies to a substance or a medicinal product are subsequently diluted several times in combination with an external action, mainly vertical shaking, until an activated form is obtained, for example, by homeopathic potentiation technology (see, for example, W. Schwabe, Homeopathic medicines. Description and manufacturing manual , M., 1967, p. 12 - 38; or G. Keller, Homeopathy, M. "Medicine” 2000, part 1, p. 37 - 40).
- homeopathic potentiation technology see, for example, W. Schwabe, Homeopathic medicines. Description and manufacturing manual , M., 1967, p. 12 - 38; or G. Keller, Homeopathy, M. "Medicine” 2000, part 1, p. 37 - 40).
- a uniform decrease in concentration is carried out by sequentially diluting 1 volume part of the starting substance (antibodies) in 9 volume parts (for decimal dilution D) or in 99 volume parts (for hundredth dilution C) or in 999 volume parts (for thousandth dilution) of a neutral solvent - distilled water and / or 70% ethyl alcohol with multiple vertical shaking of each dilution obtained and the use of mainly separate containers for each subsequent dilution to obtain Nia required dilution.
- External processing in the process of reducing the concentration can also be carried out by ultrasound or electromagnetic exposure, as well as other mechanical effects.
- the granules of the neutral substance - lactose (milk) introduced into the fluidized bed are irrigated sugar) with a particle size of 150 ⁇ 250 microns prepared water-alcohol dilution (preferably hundred) of the activated form of antibodies with simultaneous drying at a temperature not exceeding 35 ° C.
- the estimated amount of the prepared pharmaceutical substance - the active substance in the form of "saturated” lactose is loaded into the mixer and mixed with microcrystalline cellulose, introduced in an amount of 10.0 ⁇ 15.0 mass. % of the total mass of the load. Then “unsaturated” lactose is added to the mixture (if necessary, to reduce the cost and to simplify and speed up the technological process without reducing the effectiveness of the therapeutic effect by reducing the content of a pharmaceutical substance in a tablet: water-alcohol dilution of the activated form of antibodies) in an amount of 30–80 macc. % of the total mass of the load and magnesium stearate in an amount of 0.8 ⁇ 1.2 mass. % of the total mass of the load, and evenly mixed.
- the obtained dry homogeneous mixture is sent to a tabletting machine, for example, tablet - Korsh press - XL 400, to form round tablets by direct dry pressing weighing 150 ⁇ 500 mg.
- a tabletting machine for example, tablet - Korsh press - XL 400
- the following is an example of obtaining a drug in the form of an activated form of polyclonal antibodies (antisera) to morphine, the process of which proceeds in several stages.
- the step of obtaining the morphine-ovalbulin conjugate is the step of obtaining the morphine-ovalbulin conjugate.
- a solution of 50 mg (0.001 mmol) of ovalbulin in 5.0 ml of distilled water is mixed with 2.0 ml of dimethylformamide containing 15.0 mg (0.039 mmol) of morphine 6-hemicycin, and a solution of 15 mg (0.055 mmol) is added dropwise.
- water-soluble carbodiamide in 3 ml of distilled water was incubated for 5 hours at 4 ° C.
- the resulting conjugate was isolated by gel chromatography on a Sephadex G25 column and lyophilized.
- the amount of attached morphine is calculated from the UV spectra of the starting protein and the resulting conjugate from the change in absorbance at 280 nm. According to the UV spectra, the synthesized conjugate contains 12–15 moles of hapten per mole of protein.
- the immunization of “Blue Blue” rabbits weighing no more than 2 kg is carried out cyclically with a 10-day interval. The maximum number of injections is four.
- the conjugate is injected into the front and hind limbs in the region of the articular lymph nodes in an amount of 1 mg per immunization.
- the antigen is pre-dissolved in 1 ml of complete Freund's adjuvant.
- the volume of the mixture for immunization is 2 ml.
- Rabbit blood serum was obtained by centrifugation at 100Og for 10 minutes at room temperature, after which chloroform was added as a preservative to a final concentration of 13%.
- the resulting antiserum is checked by enzyme-linked immunosorbent assay for the presence of specific antibodies to morphine, the detection of which is carried out using the conjugate of antispecies antibodies labeled with the enzyme.
- antiserum contains specific antibodies at a dilution of 1: 1000 ⁇ 1: 25000.
- the ⁇ -globulin fraction is isolated from the obtained antiserum.
- protein precipitation with 50% ammonium sulfate is used, followed by washing the precipitate with 30% saline solution, centrifugation and dialysis against phosphate buffer.
- the fraction thus prepared containing specific antibodies to this antigen is used in the next step to prepare a drug.
- the step of obtaining an activated form of antibodies to morphine is a step of obtaining an activated form of antibodies to morphine.
- 0.5 ml of the fraction of ⁇ -globulin antiserum is placed in an E-6 container. 4.5 ml of distilled water are added, shaken 10 times, 5 ml of the 1st hundredth dilution are obtained. Then 0.05 ml of the 1st hundredth dilution is placed in an E-6 2 container, 4.95 ml of distilled water is added, shaken 10 times, 5.0 ml of the 2nd hundredth dilution is obtained. Similarly, the 2nd hundredth dilution is prepared from the 3rd to 29th hundredth dilution. The final 30th hundredth dilution is obtained by diluting the 29th in 70% ethanol.
- the resulting water-alcohol solution is used for fluidized bed irrigation of particles of a neutral carrier - lactose (milk sugar) in the preparation of a pharmaceutical substance - the active substance in the form of "saturated" lactose, which is the basis for the formation of direct oral compression of a solid oral form (round tablets, mainly , weighing 240 and 300 mg) of the claimed drug.
- a neutral carrier - lactose milk sugar
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2645475A CA2645475C (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medicinal preparation and a method for the production thereof |
AU2006340119A AU2006340119B2 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medicinal preparation and a method for the production thereof |
LTEP06799634.8T LT1997481T (lt) | 2006-03-13 | 2006-05-16 | Medicininio preparato solidinė peroralinė forma ir jos gavimas |
BRPI0621507-6A BRPI0621507A2 (pt) | 2006-03-13 | 2006-05-16 | método para a produção de uma forma oral sólida de uma preparação medicinal baseada em anticorpo e forma de dosagem sólida para a administração em um sujeito humano |
EP06799634.8A EP1997481B1 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medicinal preparation and a method for the production thereof |
US12/282,614 US9522116B2 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medicinal preparation and a method for the production thereof |
JP2009500312A JP5551429B2 (ja) | 2006-03-13 | 2006-05-16 | 固体の経口投与形態の医薬組成物、及びその製造方法 |
EA200801971A EA200801971A1 (ru) | 2006-03-13 | 2006-05-16 | Твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
MX2008011811A MX2008011811A (es) | 2006-03-13 | 2006-05-16 | Forma oral solida de una preparacion medicinal y un metodo para la produccion de la misma. |
CN2006800540501A CN101415403B (zh) | 2006-03-13 | 2006-05-16 | 药物制剂的固体口服剂形式及其制备方法 |
ES06799634.8T ES2651350T3 (es) | 2006-03-13 | 2006-05-16 | Forma oral sólida de una preparación medicinal y un método para la producción de la misma |
DK06799634.8T DK1997481T3 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medical composition and method of preparation thereof |
PL06799634T PL1997481T3 (pl) | 2006-03-13 | 2006-05-16 | Stała postać doustna preparatu leczniczego i sposób jego wytwarzania |
ZA2008/08631A ZA200808631B (en) | 2006-03-13 | 2008-10-09 | Solid oral form of a medicinal preparation and a method for the production thereof |
US15/349,640 US20170056499A1 (en) | 2006-03-13 | 2016-11-11 | Solid oral form of a medicinal preparation and a method for the production thereof |
CY20171101299T CY1119682T1 (el) | 2006-03-13 | 2017-12-12 | Απο του στοματος στερεα μορφη ενος φαρμακευτικου παρασκευασματος και μια μεθοδος για την παραγωγη αυτης |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006107580/15A RU2309732C1 (ru) | 2006-03-13 | 2006-03-13 | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
RU2006107580 | 2006-03-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/282,614 A-371-Of-International US9522116B2 (en) | 2006-03-13 | 2006-05-16 | Solid oral form of a medicinal preparation and a method for the production thereof |
US15/349,640 Division US20170056499A1 (en) | 2006-03-13 | 2016-11-11 | Solid oral form of a medicinal preparation and a method for the production thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007105981A1 true WO2007105981A1 (fr) | 2007-09-20 |
Family
ID=38509730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2006/000237 WO2007105981A1 (fr) | 2006-03-13 | 2006-05-16 | Forme orale solide d'une préparation médicinale et procédé de production de celle-ci |
Country Status (21)
Country | Link |
---|---|
US (2) | US9522116B2 (ru) |
EP (1) | EP1997481B1 (ru) |
JP (1) | JP5551429B2 (ru) |
KR (1) | KR20080109017A (ru) |
CN (1) | CN101415403B (ru) |
AU (1) | AU2006340119B2 (ru) |
BR (1) | BRPI0621507A2 (ru) |
CA (1) | CA2645475C (ru) |
CY (1) | CY1119682T1 (ru) |
DK (1) | DK1997481T3 (ru) |
EA (1) | EA200801971A1 (ru) |
ES (1) | ES2651350T3 (ru) |
HU (1) | HUE035265T2 (ru) |
LT (1) | LT1997481T (ru) |
MX (1) | MX2008011811A (ru) |
PL (1) | PL1997481T3 (ru) |
PT (1) | PT1997481T (ru) |
RU (1) | RU2309732C1 (ru) |
UA (1) | UA92076C2 (ru) |
WO (1) | WO2007105981A1 (ru) |
ZA (1) | ZA200808631B (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522116B2 (en) | 2006-03-13 | 2016-12-20 | Oleg Iliich Epshtein | Solid oral form of a medicinal preparation and a method for the production thereof |
WO2021040570A1 (en) | 2019-08-29 | 2021-03-04 | Oleg Iliich Epshtein | Medicament and method for treating infectious diseases |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
CA2654408C (en) * | 2006-06-06 | 2018-05-08 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
ITTO20110641A1 (it) * | 2010-07-15 | 2012-01-16 | Oleg Iliich Epshtein | Composizioni farmaceutiche e metodi di trattamento |
RU2531048C2 (ru) * | 2010-07-21 | 2014-10-20 | Мапикс Эс.Эй.Ар.Эл. | Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами |
DE112011102362T5 (de) | 2010-07-15 | 2013-04-25 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen |
RU2522499C2 (ru) * | 2010-07-27 | 2014-07-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способ лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями |
RU2523557C2 (ru) * | 2010-07-15 | 2014-07-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии |
RU2525155C2 (ru) * | 2010-07-15 | 2014-08-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности |
RU2542453C2 (ru) * | 2010-07-21 | 2015-02-20 | Олег Ильич Эпштейн | Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов |
EA030566B1 (ru) | 2010-07-15 | 2018-08-31 | Олег Ильич ЭПШТЕЙН | Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция |
RU2509573C2 (ru) * | 2010-07-27 | 2014-03-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза |
RU2525156C2 (ru) * | 2010-07-15 | 2014-08-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии |
RU2528093C2 (ru) * | 2010-07-21 | 2014-09-10 | Олег Ильич Эпштейн | Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля |
ITTO20110632A1 (it) | 2010-07-21 | 2012-01-22 | Oleg Iliich Epshtein | Metodo per trattare il disturbo da deficit di attenzione e iperattivita' |
RU2535033C2 (ru) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
DE112011102640T5 (de) * | 2010-08-06 | 2013-07-11 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten |
RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
RU2678979C2 (ru) * | 2016-05-17 | 2019-02-05 | Олег Ильич Эпштейн | Средство для использования в гомеопатической технологии |
RU2018118695A (ru) * | 2018-05-22 | 2019-11-22 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Лекарственное средство для лечения нарушений функций органа или ткани, а также заболеваний, сопровождающихся данными нарушениями, и способ его получения |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2161481C2 (ru) * | 1995-09-21 | 2001-01-10 | Фарма Пасс Ллс | Новая композиция, содержащая кислотно-нестойкий омепразол, и способ ее получения |
US6326360B1 (en) * | 1998-03-11 | 2001-12-04 | Grelan Pharmaceuticals Co., Ltd. | Bubbling enteric coated preparations |
RU2182008C1 (ru) * | 2000-10-20 | 2002-05-10 | Самойленко Игорь Иннокентьевич | Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии |
RU2201254C1 (ru) * | 2001-09-25 | 2003-03-27 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3901967A (en) | 1973-09-10 | 1975-08-26 | Union Corp | Sustained release of atropine |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
JPS61176534A (ja) * | 1985-01-30 | 1986-08-08 | Takashi Muramatsu | 避妊用剤 |
US5066491A (en) * | 1985-04-15 | 1991-11-19 | Protein Technology, Inc. | Method of disease treatment utilizing an immunologically active whey fraction |
FR2609895B1 (fr) * | 1987-01-28 | 1991-06-28 | Bruttmann Georges | Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale |
US5244663A (en) | 1987-01-28 | 1993-09-14 | Medibrevex | Therapeutic method against allergy |
JPH01252581A (ja) | 1988-03-31 | 1989-10-09 | Taiyo Yuden Co Ltd | 窒化物セラミツクスの製造方法 |
FI101344B (fi) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta |
US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
RU2007989C1 (ru) | 1991-11-12 | 1994-02-28 | Акционерное общество "Трейдис" | Способ габович подбора гомеопатических препаратов и их разовой дозы |
RU2035167C1 (ru) | 1992-07-16 | 1995-05-20 | Гальцев Юрий Викторович | Способ получения биологически активного водного раствора меда |
DE69312077T2 (de) | 1992-10-08 | 1997-10-30 | Kennedy Inst Of Rheumatology | Behandlung von autoimmun- und entzundungskrankheiten |
US5879677A (en) | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
RU2033784C1 (ru) | 1993-05-28 | 1995-04-30 | Индивидуальное частное предприятие "Диалог" | Устройство для репродуцирования гомеопатических и изопатических препаратов |
JPH073754A (ja) | 1993-06-17 | 1995-01-06 | Marsima Aqua Syst Corp | 魚道ゲート |
IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
EP0725789B1 (en) | 1993-09-20 | 2003-03-19 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
NZ278607A (en) | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
US5629286A (en) | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
IL110035A0 (en) | 1994-06-16 | 1994-10-07 | Tapuach Natural Technologies 1 | Homeopathic formulations |
DK0859612T3 (da) * | 1995-09-21 | 2003-09-22 | Pharma Pass Ii Llc | Farmaceutisk sammensætning indeholdende en syre-labil omeprazol og fremgangsmåde til fremstilling deraf |
EP0884042A4 (en) | 1996-02-12 | 2006-01-04 | Oleg Iliich Epshtein | MEDICAMENT AND METHOD FOR TREATING AN ORGANISM WITH THIS |
US5834443A (en) | 1996-05-21 | 1998-11-10 | Masiello; Domenick J. | Composition and method for treating herpes simplex |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
RU2114605C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Защитная добавка для косметических средств |
RU2114646C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Способ повышения защитных свойств организма при воздействии внешних физических факторов |
RU2132181C1 (ru) | 1996-09-30 | 1999-06-27 | Эпштейн Олег Ильич | Средство для воздействия на организм |
JPH10212246A (ja) * | 1997-01-30 | 1998-08-11 | Nippon Zoki Pharmaceut Co Ltd | 経口投与用製剤 |
RU2103999C1 (ru) | 1997-01-31 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения алкоголизма |
RU2104006C1 (ru) | 1997-02-14 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения наркомании |
DE19746868A1 (de) | 1997-10-23 | 1999-04-29 | Knoll Ag | Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen |
RU2122858C1 (ru) | 1997-12-29 | 1998-12-10 | Яковлева Людмила Борисовна | Гомеопатическое лекарственное средство седативного действия "вернисон" |
RU2133123C1 (ru) | 1997-12-29 | 1999-07-20 | Эпштейн Олег Ильич | Гомеопатическое лекарственное средство для лечения диспептических расстройств "нетизжог" |
RU2187334C2 (ru) | 1998-05-22 | 2002-08-20 | Эпштейн Олег Ильич | Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
JP2000302691A (ja) * | 1999-02-17 | 2000-10-31 | Biomed Comm Inc | 精製成長ホルモンのホメオパシー調製剤 |
RU2161955C1 (ru) | 1999-07-16 | 2001-01-20 | Эпштейн Олег Ильич | Способ изменения физико-химических или физико-химических и биологических свойств вещества |
RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
RU2182492C1 (ru) | 2000-12-14 | 2002-05-20 | Эпштейн Олег Ильич | Лекарственное средство для лечения наркотической зависимости |
RU2191601C1 (ru) | 2001-04-18 | 2002-10-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эректильных дисфункций |
RU2192882C1 (ru) | 2001-04-18 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения |
RU2201255C1 (ru) | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
RU2209083C1 (ru) | 2001-12-26 | 2003-07-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения кашля |
FR2836379B1 (fr) * | 2002-02-28 | 2007-06-01 | Dit Bon Michel Betend | Formes galeniques solides de medicaments homeopathiques, dont les allergenes ou antigenes, en dilutions homeopathiques pour preparation extemporanee pour un seul individu pour administration sublinguale |
UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
UA76641C2 (ru) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатическое лекарственное средство и способ лечения заболеваний предстательной железы |
UA76640C2 (ru) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Способ коррекции патологических иммунных реакций и гомеопатическое лекарственное средство |
UA76639C2 (ru) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатическое лекарственное средство и способ лечения эректильных дисфункций |
FR2851918B1 (fr) * | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
RU2253478C1 (ru) | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества |
RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
CA2654408C (en) | 2006-06-06 | 2018-05-08 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
US20130189707A1 (en) | 2010-01-26 | 2013-07-25 | Svetlana Alexandrovna Sergeeva | Method of determination of autoantibody level by means of enzyme immunoassay |
ITTO20110641A1 (it) | 2010-07-15 | 2012-01-16 | Oleg Iliich Epshtein | Composizioni farmaceutiche e metodi di trattamento |
ES2425314R1 (es) | 2010-07-15 | 2014-07-09 | Oleg Iliich Epshtein | Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario |
EA030542B1 (ru) | 2010-07-15 | 2018-08-31 | Олег Ильич ЭПШТЕЙН | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии |
WO2012007846A2 (en) | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system |
DE112011102362T5 (de) | 2010-07-15 | 2013-04-25 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen |
MX2013000804A (es) | 2010-07-21 | 2013-10-28 | Oleg Iliich Epshtein | Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos. |
ES2446643R1 (es) | 2010-07-21 | 2015-03-06 | Oleg Iliich Epshtein | Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular |
CA2805978C (en) | 2010-07-21 | 2016-06-28 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition |
ITTO20110632A1 (it) | 2010-07-21 | 2012-01-22 | Oleg Iliich Epshtein | Metodo per trattare il disturbo da deficit di attenzione e iperattivita' |
CN103119060A (zh) | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | 治疗阿尔兹海默病的方法 |
ITTO20110634A1 (it) | 2010-07-21 | 2012-01-22 | Oleg Iliich Epshtein | Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia |
RU2535033C2 (ru) | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
RU2517084C2 (ru) | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
DE112011102640T5 (de) | 2010-08-06 | 2013-07-11 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten |
US20120263725A1 (en) | 2010-08-06 | 2012-10-18 | Epshtein Oleg Iiiich | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV |
RU2535034C2 (ru) | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
US20130171161A1 (en) | 2010-12-23 | 2013-07-04 | Oleg Iliich Epshtein | Method and composition for the treatment of diseases caused by or associated with hiv |
-
2006
- 2006-03-13 RU RU2006107580/15A patent/RU2309732C1/ru not_active IP Right Cessation
- 2006-05-16 UA UAA200812133A patent/UA92076C2/ru unknown
- 2006-05-16 US US12/282,614 patent/US9522116B2/en active Active
- 2006-05-16 MX MX2008011811A patent/MX2008011811A/es active IP Right Grant
- 2006-05-16 ES ES06799634.8T patent/ES2651350T3/es active Active
- 2006-05-16 PL PL06799634T patent/PL1997481T3/pl unknown
- 2006-05-16 WO PCT/RU2006/000237 patent/WO2007105981A1/ru active Application Filing
- 2006-05-16 JP JP2009500312A patent/JP5551429B2/ja not_active Expired - Fee Related
- 2006-05-16 DK DK06799634.8T patent/DK1997481T3/en active
- 2006-05-16 EP EP06799634.8A patent/EP1997481B1/en not_active Not-in-force
- 2006-05-16 LT LTEP06799634.8T patent/LT1997481T/lt unknown
- 2006-05-16 CA CA2645475A patent/CA2645475C/en not_active Expired - Fee Related
- 2006-05-16 AU AU2006340119A patent/AU2006340119B2/en not_active Ceased
- 2006-05-16 EA EA200801971A patent/EA200801971A1/ru unknown
- 2006-05-16 KR KR1020087024607A patent/KR20080109017A/ko not_active Application Discontinuation
- 2006-05-16 HU HUE06799634A patent/HUE035265T2/en unknown
- 2006-05-16 BR BRPI0621507-6A patent/BRPI0621507A2/pt not_active IP Right Cessation
- 2006-05-16 CN CN2006800540501A patent/CN101415403B/zh not_active Expired - Fee Related
- 2006-05-16 PT PT67996348T patent/PT1997481T/pt unknown
-
2008
- 2008-10-09 ZA ZA2008/08631A patent/ZA200808631B/en unknown
-
2016
- 2016-11-11 US US15/349,640 patent/US20170056499A1/en not_active Abandoned
-
2017
- 2017-12-12 CY CY20171101299T patent/CY1119682T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2161481C2 (ru) * | 1995-09-21 | 2001-01-10 | Фарма Пасс Ллс | Новая композиция, содержащая кислотно-нестойкий омепразол, и способ ее получения |
US6326360B1 (en) * | 1998-03-11 | 2001-12-04 | Grelan Pharmaceuticals Co., Ltd. | Bubbling enteric coated preparations |
RU2182008C1 (ru) * | 2000-10-20 | 2002-05-10 | Самойленко Игорь Иннокентьевич | Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии |
RU2201254C1 (ru) * | 2001-09-25 | 2003-03-27 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
Non-Patent Citations (4)
Title |
---|
"Drug Encyclopedia", 2000, article "Russian Drug Register", pages: 358 - 359 |
"Immunological methods", 1987, article "Meditsina", pages: 9 - 33 |
See also references of EP1997481A4 * |
V. SHVABE: "A description and preparation guide", HOMEOPATHIC DRUGS, 1967, pages 12 - 38 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522116B2 (en) | 2006-03-13 | 2016-12-20 | Oleg Iliich Epshtein | Solid oral form of a medicinal preparation and a method for the production thereof |
WO2021040570A1 (en) | 2019-08-29 | 2021-03-04 | Oleg Iliich Epshtein | Medicament and method for treating infectious diseases |
Also Published As
Publication number | Publication date |
---|---|
ES2651350T3 (es) | 2018-01-25 |
DK1997481T3 (en) | 2017-12-11 |
KR20080109017A (ko) | 2008-12-16 |
UA92076C2 (ru) | 2010-09-27 |
CY1119682T1 (el) | 2018-04-04 |
JP2009530271A (ja) | 2009-08-27 |
BRPI0621507A2 (pt) | 2011-12-13 |
CA2645475A1 (en) | 2007-09-20 |
MX2008011811A (es) | 2009-02-06 |
US9522116B2 (en) | 2016-12-20 |
CA2645475C (en) | 2015-03-17 |
PL1997481T3 (pl) | 2018-02-28 |
ZA200808631B (en) | 2009-12-30 |
PT1997481T (pt) | 2017-12-18 |
CN101415403A (zh) | 2009-04-22 |
AU2006340119A1 (en) | 2007-09-20 |
US20090148521A1 (en) | 2009-06-11 |
JP5551429B2 (ja) | 2014-07-16 |
RU2309732C1 (ru) | 2007-11-10 |
EP1997481A4 (en) | 2011-04-20 |
EA200801971A1 (ru) | 2009-02-27 |
EP1997481B1 (en) | 2017-09-13 |
HUE035265T2 (en) | 2018-05-02 |
CN101415403B (zh) | 2013-07-10 |
US20170056499A1 (en) | 2017-03-02 |
AU2006340119B2 (en) | 2012-01-12 |
EP1997481A1 (en) | 2008-12-03 |
LT1997481T (lt) | 2018-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2309732C1 (ru) | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата | |
AU2011287292B2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
US20110008452A1 (en) | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance | |
RU2535033C2 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
RU2182492C1 (ru) | Лекарственное средство для лечения наркотической зависимости | |
RU2209084C1 (ru) | Лекарственное средство и способ лечения депрессивных расстройств | |
RU2437678C2 (ru) | Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения | |
RU2502521C2 (ru) | Комплексное лекарственное средство для лечения бактериальных инфекций и способ лечения бактериальных инфекций | |
RU2500427C2 (ru) | Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта | |
RU2533224C2 (ru) | Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения | |
RU2526153C2 (ru) | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция | |
RU2536232C2 (ru) | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера | |
RU2528093C2 (ru) | Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля | |
RU2517085C2 (ru) | Комплексное лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
RU2532323C2 (ru) | Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника | |
RU2441023C1 (ru) | Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза | |
RU2509573C2 (ru) | Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза | |
RU2531049C2 (ru) | Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы | |
RU2651005C2 (ru) | Способ повышения фармакологической активности активированной-потенцированной формы антител к простатоспецифическому антигену и фармацевтическая композиция | |
RU2595809C2 (ru) | Лекарственное средство | |
RU2542414C2 (ru) | Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций | |
RU2523451C2 (ru) | Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06799634 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2645475 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 194062 Country of ref document: IL Ref document number: 2008091527 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008502066 Country of ref document: PH Ref document number: MX/A/2008/011811 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009500312 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680054050.1 Country of ref document: CN |
|
REEP | Request for entry into the european phase |
Ref document number: 2006799634 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8493/DELNP/2008 Country of ref document: IN Ref document number: 2006799634 Country of ref document: EP Ref document number: 1020087024607 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006340119 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200801971 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006340119 Country of ref document: AU Date of ref document: 20060516 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12282614 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0621507 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080915 |